Global Blood Therapeutics, Inc. (GBT) will report its next earnings on Aug 06 AMC. The company reported the earnings of $-0.87/Share in the last quarter where the estimated EPS by analysts was $-0.91/share. The difference between the expected and actual EPS was $0.04/share, which represents an Earnings surprise of 4.4%.
Many analysts are providing their Estimated Earnings analysis for Global Blood Therapeutics, Inc. and for the current quarter 13 analysts have projected that the stock could give an Average Earnings estimate of $-0.88/share. These analysts have also projected a Low Estimate of $-0.99/share and a High Estimate of $-0.79/share.
Some buy side analysts are also providing their Analysis on Global Blood Therapeutics, Inc., where 3 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Global Blood Therapeutics, Inc. might touch $125 high while the Average Price Target and Low price Target is $82.33 and $59 respectively.
The Relative Volume of the company is 1.96 and Average Volume (3 months) is 1.17 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of -35.7%. The Return on Equity (ROE) value stands at -38.7%.
While looking at the Stock’s Performance, Global Blood Therapeutics, Inc. currently shows a Weekly Performance of -5.36%, where Monthly Performance is -12.03%, Quarterly performance is -13.89%, 6 Months performance is 2.53% and yearly performance percentage is 43.97%. Year to Date performance value (YTD perf) value is 3.18%. The Stock currently has a Weekly Volatility of 6.72% and Monthly Volatility of 9.24%.